Life Sciences Tools and Instruments Bi-Weekly Industry Events & M&A Update — September 14–28, 2026

Read the report

SlidesScroll

1 of 7

←→Full screen

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES TOOLS AND INSTRUMENTS

Clinical Migration Pulls the Sector Higher as New Launches Land

What moved, what companies did, and what changed in the transaction record across Life Sciences Tools and Instruments from September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Life Sciences Tools and Instruments Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

Sources & methodology

1

← Previous

1 / 7 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES TOOLS AND INSTRUMENTS

Next →

What each page shows

The analyst’s walkthrough of the deck, page by page.

1. 01
   BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

   HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES TOOLS AND INSTRUMENTS

   Cover slide introducing the bi-weekly Life Sciences Tools and Instruments industry events and M&A update for September 14–28, 2026.

   We open with the two-week lens on Life Sciences Tools and Instruments, covering what changed, who moved, what transacted, and what it means. This report gives clients a fast, evidence-based read on the sector heading into the next two weeks.

   Everything on this page

   BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › LIFE SCIENCES TOOLS AND INSTRUMENTS Clinical Migration Pulls the Sector Higher as New Launches Land What moved, what companies did, and what changed in the transaction record across Life Sciences Tools and Instruments from September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Life Sciences Tools and Instruments Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

2. 02
   THE BI-WEEKLY BOTTOM LINE

   Launches Aimed at Regulated Workflows, Not New Transactions, Carried the Period

   Summarizes the two-week period: covered names' price moves, the leading mover, product launches, and the absence of new transactions.

   Eleven of the twelve names we cover rose over the period, with the median move at +18.2% against +0.8% for the S&P 500. Pacific Biosciences led the group at +26.7%, while product launches from Revvity, Agilent and Cytek pointed to a shared push into clinical and regulated workflows. No new transactions were signed, leaving the trailing record of 40 precedent deals at a median 19.5x multiple as the reference. For clients, the signal this period was organic: menu expansion and workflow ownership, not new deal-making, drove the tape.

   Everything on this page

   THE BI-WEEKLY BOTTOM LINE Launches Aimed at Regulated Workflows, Not New Transactions, Carried the Period The two-week period in one page · 12 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Life Sciences Tools and Instruments Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 11 of 12 Covered Names Rose; The Median Move Was +18.2% The covered set ran well ahead of the S&P 500, which returned +0.8% over the same two-week period. Only one covered name finished lower. 2 Pacific Biosciences Led the Covered Set PACB returned +26.7% over the two-week period, with its largest single day, +12.1%, on Sep 24. Zacks reported closes of $1.38 on Sep 17 and $1.62 on Sep 25. 3 Companies Spent the Period Extending the Assay Menu into Clinical Use Revvity, Inc. (RVTY) launched a CE-IVDR-certified multiplex screening kit, Agilent Technologies, Inc. (A) launched TapeStationDx for clinical NGS sample quality control, and Cytek Biosciences, Inc. (CTKB) extended its cloud analysis tools. The NeuraCap read: the work this period went into menu and workflow ownership rather than placements alone. 4 No New Transactions Signed; The Trailing Record Remains the Reference No material sector transactions were announced during the period. The trailing record of 40 precedent transactions carries a median of 19.5x EV / EBITDA, and Bio-Techne Corporation (TECH) shareholders approved their already-agreed merger on Sep 23. +26.7% Best mover — PACB worst: MXCT -1.7% · 11 up / 1 down of 12 covered +18.2% Sector median two-week return vs S&P 500 +0.8%

3. 03
   PUBLIC MARKET MOVERS

   A Core-Tier Sequencing Platform Set the Pace While One Discount-Tier Name Sat Out

   Shows the two-week price performance of covered names, led by a core-tier sequencing platform, against sector and index benchmarks.

   Pacific Biosciences set the pace this period, moving +26.7% including a single-day gain of +12.1%. The broader covered set's median move of +18.2% ran well ahead of the S&P 500's +0.8%, with our materiality bar set at +27.3% on a sector-relative basis. One discount-tier name sat out the rally, underscoring that the move was concentrated rather than universal. We read the dispersion as evidence the market is pricing execution and positioning differences within the sector, not lifting every name equally.

   Everything on this page

   PUBLIC MARKET MOVERS A Core-Tier Sequencing Platform Set the Pace While One Discount-Tier Name Sat Out Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median +18.2% · S&P 500 +0.8% · materiality bar ±27.3% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Life Sciences Tools and Instruments Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median +18.2% Pacific Biosciences of California, Inc. (PACB) +26.7% Shares of Pacific Biosciences of California, Inc. (PACB) moved following the Sep 20 report that the company is sharpening execution around clinical genomics, cost controls and $40M of savings behind its HiFi sequencing push. A Core-tier platform can re-rate on clinical positioning and cost discipline before placements show it. COMPANY-SPECIFIC MaxCyte, Inc. (MXCT) -1.7% No notable in-window news was identified that clearly explains the move. MaxCyte, Inc. (MXCT) returned -1.7% against a covered-set median of +18.2%. A Discount-tier name can stand apart from a broad advance across the covered set. UNEXPLAINED

4. 04
   MAJOR NEWS & INDUSTRY CATALYSTS

   What Companies Actually Did: Menu Expansion, Workflow Ownership and One Shareholder Vote

   Details the period's highest-impact company actions, including menu expansion launches and one shareholder vote.

   The period's real work happened in product and workflow decisions: Revvity launched a CE-IVDR-certified multiplex screening kit, Agilent introduced TapeStationDx for clinical NGS sample quality control, and Cytek extended its cloud analysis tools. Bio-Techne shareholders also approved their already-agreed merger, a governance milestone rather than a new deal. Each of these actions signals a push to own more of the regulated, clinical workflow rather than simply placing instruments. For clients, the throughline is clear: menu and workflow ownership, not transaction volume, defined the period's catalysts.

   Everything on this page

   MAJOR NEWS & INDUSTRY CATALYSTS What Companies Actually Did: Menu Expansion, Workflow Ownership and One Shareholder Vote The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Life Sciences Tools and Instruments Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 24 · NEWS · Business Wire Revvity launches a CE-IVDR-certified multiplex kit for early detection of type 1 diabetes A fully automated, IVDR-certified kit aimed at population-wide screening moves a Premium-tier assay menu from research use into a regulated clinical setting. Regulated menu expansion raises pull-through on an existing installed base. Sep 23 · NEWS · GlobeNewsWire MaxCyte appoints Sidharth Kapileshwar as Chief Corporate Development Officer Adding a dedicated corporate development seat signals a cell engineering platform building capacity to pursue partnerships and portfolio moves from a Discount-tier starting point. Platform companies often build corporate development capability before the record shows activity. Sep 23 · NEWS · PRNewsWire Bio-Techne shareholders vote to approve and adopt the definitive merger agreement A Premium-tier reagents and diagnostics franchise cleared its shareholder vote on an already-agreed transaction. The NeuraCap read: scaled strategic appetite for proprietary consumables streams remains live. Proprietary chemistry and reagent IP remain the assets buyers pursue in this sector. Sep 23 · NEWS · GlobeNewsWire Cytek adds a Cloud Analysis tool, extending its Cytek Cloud digital ecosystem Adding analysis to instruments and reagents moves the company closer to owning the full sample-to-answer path in flow cytometry rather than supplying one step inside someone else's workflow. Software attached to the installed base defends workflow ownership without new placements. Sep 22 · NEWS · PRNewsWire Bio-Techne opens a Düsseldorf customer experience centre serving DACH and EMEA Hands-on access to technologies and workflows is how validated methods spread and switching costs build. It also thickens the service and training footprint behind the aftermarket annuity. Service network density is a value driver, not an overhead line. Sep 22 · NEWS · PRNewsWire Danaher schedules its third-quarter 2026 earnings call for October 21 A calendar item rather than new information. It sets the date on which a Core-tier diversified platform gives the sector its next read on instrument demand and book-to-bill. The next demand signal for the group is dated, not delivered.

5. 05
   M&A & STRATEGIC ACTIVITY

   Operators Built; The Transaction Record Stood Still

   Reports that no new transactions were announced, leaving the trailing precedent record as the pricing reference.

   No material sector transactions were announced during the two-week period, so the deal record held steady rather than moved. The trailing set of 40 precedent transactions carries a median of 19.5x, and this remains the pricing frame for any conversation with acquirers today. Bio-Techne's shareholder approval of its already-agreed merger was the only deal-related event of note, a procedural step rather than a new signing. For advisors, the quiet transaction tape means the existing multiple set still anchors valuation discussions until new deals reset it.

   Everything on this page

   M&A & STRATEGIC ACTIVITY Operators Built; The Transaction Record Stood Still September 14–28, 2026 · precedent transactions: 40 recorded deals · median 19.5x EV/LTM EBITDA Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Life Sciences Tools and Instruments Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. The only transaction-related development was the Bio-Techne Corporation (TECH) shareholder approval of an already-agreed merger, leaving the trailing record of 40 precedent transactions, at a median of 19.5x EV / EBITDA A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 40 Recorded precedent transactions the reference set buyers and sellers price against 19.5x Precedent median EV/LTM EBITDA LTM at announcement, where disclosed

6. 06
   WHAT IT MEANS

   What the Two-Week Period Changes for Operators, Buyers and Advisors

   Translates the period's evidence into distinct takeaways for operators, acquirers and advisors.

   For owners and operators, the lesson is that menu and mix did the work this period, with prices moving on regulated-workflow news rather than deal announcements. For acquirers, the reference set is unchanged: with 40 precedent transactions still at a median 19.5x, the pricing conversation continues from where it left off. For advisors, the strongest story to lead with is the migration from research-use-only into clinical and screening workflows, a theme that coincided with 11 of 12 covered names rising at a median +18.2% move. Together, these reads point clients toward positioning around regulated-workflow ownership rather than waiting on new transaction catalysts.

   Everything on this page

   WHAT IT MEANS What the Two-Week Period Changes for Operators, Buyers and Advisors The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Life Sciences Tools and Instruments Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 5.2x 12 companies in the study 3 valuation tiers Standing thesis: Life Sciences Tools prices cell and gene therapy platforms differently from laboratory monitoring instruments FOR OWNERS & OPERATORS Menu and Mix Did the Work This Period Companies in the space traded higher while the news flow was about assay menu, clinical positioning and workflow ownership. FOR ACQUIRERS The Reference Set Is Unchanged; The Asset Quality Question Moved No new transactions were signed, so the trailing record of 40 precedent transactions at a median of 19.5x EV / EBITDA still frames pricing. FOR ADVISORS Lead with the Research-to-Regulated Story The dominant theme was migration from research-use-only into clinical and screening workflows, and the covered set rose with it: 11 of 12 covered names rose; the median move was +18.2%.

7. 07
   SOURCES & METHODOLOGY

   Sources, Methodology and Important Notice

   Explains the sources and methodology behind the update's figures and calibrated language.

   Every figure in this update is drawn from a specific record — SEC filings, consensus estimates or market prices — and links back to that source. Our driver attributions use calibrated language and represent our read of the recorded evidence, not asserted causation. Where no driver is recorded for a move, the report says so explicitly rather than guessing. This discipline is what lets clients rely on the report as a fast, defensible starting point for their own diligence.

   Everything on this page

   SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Life Sciences Tools and Instruments Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. No covered name fell below the floor in this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T212308Z_570_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: businesswire.com · globenewswire.com · prnewswire.com

More coverage in Health Care

• Sector Report · Sep 28, 2026Life Sciences Tools and Instruments Sector Outlook — September 2026
• Bi-Weekly Update · Sep 28, 2026Medical Imaging Equipment Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
• Sector Report · Sep 28, 2026Medical Imaging Equipment Sector Outlook — September 2026
• Bi-Weekly Update · Sep 28, 2026Neurology and CNS Therapeutics Bi-Weekly Industry Events & M&A Update — September 14–28, 2026